Zogenix Gets the Thumbs-Down
Shares of Zogenix fell 45% after a Food and Drug Administration advisory committee reviewing its extended-release painkiller Zohydro voted 11-2 against the drug. Much of the resistance from the committee focused on potential abuse of the drug, and Zohydro in its current form is not crush-resistant. In this video, Motley Fool health care bureau chief Brenton Flynn tells us why this is such a devastating blow for the company, and what, if anything, in Zogenix's pipeline may save it.
Zogenix is a prime example of the big losses you can experience investing in unproven biotech stocks. That's why here at The Motley Fool we believe the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Zogenix Gets the Thumbs-Down originally appeared on Fool.com.Brenton Flynn, Max Macaluso, and The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Covidien Ltd. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.